The logo of Danish pharmaceutical company is pictured at their headquarters in Bagsvaerd outside of Copenhagen, Denmark on February 1, 2017.Wegovy obesity drug maker Novo Nordisk surpassed Tesla in market value Thursday, after fresh early trial data showed positive results for its new experimental weight loss pill.Shares of the Danish company hit a record high in the previous session, rallying by as much as 8%, after telling investors that a Phase I trial of the company's amycretin pill showed 13.1% weight ...

Novo Nordisk (NYSE:NVO)'s shares are significantly overvalued, based on analysis shared by the American bank Jefferies in a note to clients. It said that, as ever, Novo delivered its 'usual polished performance' at its capital markets day earlier this week, but added "we struggle to justify the stock uptick". Year-to-date, the shares are up by a third, while the past five years have seen the company's valuation grow by more than 400% on the back of the success of its diabetes-turned-weight loss drugs. Today ...

Novo Nordisk on Thursday surpassed Tesla in market valuation after the maker of the popular weight-loss drug Wegovy and Ozempic announced positive early trial data for a highly anticipated new obesity drug.Shares surged more than 8% to record highs, shooting Novo Nordisk up in global rankings to the 12th most valuable company from 14 previously, after it told investors a Phase I trial of the pill version of experimental drug amycretin showed participants lost 13.1% of their weight after 12 weeks.That compar ...

Shares of Novo Nordisk (NVO 10.41%) were jumping 9.6% higher as of 11:25 a.m. ET on Thursday. The big biopharmaceutical company is accustomed to enjoying major catalysts from news related to its type 2 diabetes drug Ozempic and weight-loss drug Wegovy. In this case, though, another product took center stage.Novo Nordisk hosted its Capital Markets Day on Thursday to update investors about its progress. During this event, the company reported results from a phase 1 study evaluating the experimental obesity dr ...

Novo Nordisk A/S (NYSE:NVO) stock is gapping to record highs today, after the pharmaceutical company reported positive phase 1 trial results for its experimental weight-loss drug, amycretin. Showing higher weight loss than its already rabidly popular Wegovy, the drug is fully in the ring of contenders, with phase 2 results due out early 2026. At last glance, NVO was up 9.2% at $136.23, and earlier peaked at $136.50. The stock has finished 10 of the last 12 weeks higher, and sports a 92% year-over-year gain. ...

KEY TAKEAWAYSNovo Nordisk's experimental weight loss treatment amcryetin reportedly shows promising results in a Phase I trial.Early results suggest that it may be more effective than the highly popular Wegovy.The Phase II trial of the drug will be launched in the second half of 2024, with results expected in early 2026.Novo Nordisk's shares jumped to a new record high and were up more than 8% in early trading Thursday in New York. The American depositary receipts (ADRs) of Novo Nordisk A/S (NVO) gained mor ...

ToplineNovo Nordisk is now worth more than Elon Musk’s electric vehicle giant Tesla, after shares of the Danish maker of Ozempic surged following the release of promising results for an oral weight loss treatment.Elon Musk, Wegovy user and Tesla CEO.Getty Images for The New York Times Key FactsNovo Nordisk’s market capitalization surged Thursday to almost $610 billion after its stock gained 9% to a record high, after the pharmaceutical firm shared that participants in a trial for an experimental amycretin p ...

Novo Nordisk (NYSE:NVO) stock is soaring higher on Thursday after the pharmaceutical company announced results from a weight loss drug clinical trial.The big news here is the company’s oral weight loss drug amycretin producing 13.1% weight loss in patients after 12 weeks. That’s a major improvement over the 6% weight loss produced by the company’s own injectable drug Wegovy.Following this success, Novo Nordisk has announced plans for a Phase 2 clinical trial of amycretin. The company intends to start this t ...

Novo Nordisk (NYSE:NVO) unveiled a potential game changer during its Capital Markets Day with data on experimental obesity pill amycredtin potentially outperforming its blockbuster drug Wegovy. An early-stage test conducted over 12 weeks showed patients taking the pill lost 13% of their weight. Though trials are still in their early stages, Novo Nordisk (NYSE:NVO) hopes it can add another killer app to its portfolio of weight-loss drugs. The successes of Wegovy and Novo Nordisk’s other injection-based obesi ...

ToplineShares of Danish pharma giant Novo Nordisk soared to a record high on Thursday after it reported promising data on a new weight loss pill, a sign of the company’s plans to cement its prime position in the burgeoning obesity drug market in the face of stiff competition from industry titans like Eli Lilly and an array of smaller biotech startups.Early data on the pill suggested it may outperform Wegovy, an injectable prescription weight loss ... [+] medicine.UCG/Universal Images Group via Getty Images ...